Table 3.
Anthropometric Data, Blood Tests Results
| Feature | Group 1 – Patients Without RH N=44 (±SD) | Group 2 – Patients With RH N=134 (±SD) | P-value |
|---|---|---|---|
| Age (years) | 34.1±0.4 | 36.7±0.4 | 0.46 |
| Gender (male, n(%)) | 7(15.9) | 21(15.7) | 0.97 |
| Arterial Hypertension (n (%)) | 9(20.5) | 19(14.2) | 0.32 |
| Dyslipidemia | 17(38.6) | 33(24.6) | 0.07 |
| Body mass (kg) | 92.9±26.3 | 77.4±22.1 | 0.0006 |
| BMI (kg/m²) | 32.2±8.5 | 27.6±7.4 | 0.001 |
| HOMA-IR | 2.7±2.14 | 1.9±1.6 | 0.02 |
| Fasting glycemia (mg/dl) | 87.4±9.1 | 83.3±9.1 | 0.02 |
| 1st hour OGTT glycemia (mg/dl) | 125.9±42.4 | 132.1±43.9 | 0.25 |
| 2nd hour OGTT glycemia (mg/dl) | 106.6±27.8 | 102.3±35 | 0.42 |
| 3rd hour OGTT glycemia (mg/dl) | 85.4±13.3 | 73.5±22.6 | 0.00001 |
| 4th hour OGTT glycemia (mg/dl) | 80.4±9.2 | 66.9±10.9 | 0.000001 |
| 5th hour OGTT glycemia (mg/dl) | 81.4±7.6 | 76.4±8.8 | 0.0005 |
| Impaired fasting glucose (n (%)) | 3(6.8) | 6(4.5) | 0.54 |
| Impaired glucose tolerance and diabetes mellitus (n (%)) | 6(13.6) | 18(13.4) | 0.97 |
| Fasting insulin (mIU/L) | 12.4±8.7 | 9.7±7.6 | 0.04 |
| Insulin: 1 hour after glucose administration (mIU/L) | 77.3±52.7 | 83.8±55.3 | 0.35 |
| Insulin: 2 hours after glucose administration (mIU/L) | 62.4±56.7 | 69±71.2 | 0.51 |
| Insulin: 3 hours after glucose administration (mIU/L) | 24.9±24.4 | 26.4±42 | 0.41 |
| Insulin: 4 hours after glucose administration (mIU/L) | 16.1±35.6 | 10.2±22.2 | 0.008 |
| Insulin: 5 hours after glucose administration (mIU/L) | 12.3±20.3 | 6.3±5.5 | 0.01 |
| Total cholesterol (mg/dL) | 183.3±32.7 | 179.6±37.7 | 0.61 |
| LDL-cholesterol (mg/dL) | 102.9±35.1 | 96.5±31.4 | 0.31 |
| HDL-cholesterol (mg/dL) | 54.3±18.8 | 63±18.5 | 0.003 |
| Triglycerides (mg/dL) | 129.1±75.9 | 104.9±63.3 | 0.02 |
| Cortisol 8:00 AM (μg/dL) | 14±7.2 | 13.4±5.2 | 0.78 |
| TSH (μU/mL) | 1.8±1.13 | 1.93±1.1 | 0.48 |
| Creatinine (mg/dL) | 0.8±0.1 | 0.8±0.1 | 0.97 |
| CRI-I | 3.7±1.2 | 3.1±1.3 | 0.004 |
| CRI-II | 2.1±0.9 | 1.7±0.9 | 0.007 |
| AIP | 0.34±0.33 | 0.18±0.3 | 0.006 |
| AC | 2.7±1.2 | 2.1±1.3 | 0.004 |
| Acetylosalicylic acid (n (%)) | 1(2.3) | 2(1.5) | 0.72 |
| ACEI (n (%)) | 3(6.8) | 11(8.2) | 0.76 |
| Angiotensin receptor blockers (n (%)) | 0(0) | 2(1.5) | 0.41 |
| Beta-adrenergic blocking agents (n (%)) | 5(11.4) | 14(10.4) | 0.86 |
| Indapamide (n (%)) | 3(6.8) | 4(2.9) | 0.26 |
| Alpha blockers (n (%)) | 2(4.5) | 2(1.5) | 0.24 |
| Calcium channel blockers (n (%)) | 1(2.3) | 8(5.9) | 0.33 |
Abbreviations: RH, reactive hypoglycemia; BMI, body mass index; HOMA-IR, homeostatic model assessment for insulin resistance; OGTT, oral glucose tolerance test; LDL, low density lipoprotein; HDL, high density lipoprotein; TSH, thyroid stimulating hormone; CRI-I, Castelli’s Risk Index I; CRI-II, Castelli’s Risk Index II; AIP, Atherogenic Index of Plasma; AC, Atherogenic Coefficient; ACEI, Angiotensin-converting enzyme inhibitors.